This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Biological therapies for rheumatoid arthritis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • biologic therapies include the tumour necrosis factor (TNF) alpha inhibitors, (etanercept, infliximab and adalimumab), rituximab and anakinra
  • NICE suggest that:
    • on the balance of its clinical benefits and cost effectiveness, anakinra is not recommended for the treatment of rheumatoid arthritis (RA), except in the context of a controlled, long-term clinical study
    • patients currently receiving anakinra for RA may suffer loss of wellbeing if their treatment were discontinued at a time they did not anticipate. Therefore, patients should continue therapy with anakinra until they and their consultant consider it is appropriate to stop
    • do not offer the combination of tumour necrosis factor- alpha inhibitor therapy and anakinra for RA

Reference:

  1. NICE (February 2009). Rheumatoid arthritis- The management of rheumatoid arthritis in adults

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.